Pomerantz LLP is investigating Regeneron Pharmaceuticals for potential securities fraud following the company's announcement that a Phase 3 trial for its cancer drug combo failed to meet key goals. The trial results, disclosed on May 15, 2026, showed no significant improvement in progression-free survival compared to existing treatment, causing Regeneron's stock to drop nearly 10%. The investigation targets whether Regeneron and some executives engaged in unlawful practices. Investors affected by the stock drop are encouraged to contact Pomerantz LLP for possible legal action.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
Regeneron Pharmaceuticals is rated a Buy due to strong growth in its EYLEA HD product, which saw U.S. sales increase by 52% in Q1 2026, offsetting competition and patient switching. The company also benefits from robust growth of DUPIXENT and a diver...
